Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | SQLE | Q14534 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13207141 | 0.85 | EPHX2 (0.47) | EPHX2EPHX1OPRL1MAPT | |
| SCHEMBL5013508 | 0.85 | EPHX2 (0.47) | EPHX2EPHX1OPRL1MAPT | |
| SCHEMBL24481225 | 0.81 | EPHX2 (0.50) | EPHX2EPHX1OPRL1MAPT | |
| SCHEMBL11897006 | 0.81 | EPHX2 (0.50) | EPHX2EPHX1OPRL1MAPT | |
| SCHEMBL3377999 | 0.80 | EPHX2 (0.46) | EPHX2EPHX1OPRL1MAPT | |
| SCHEMBL13207153 | 0.79 | EPHX2 (0.49) | EPHX2EPHX1OPRL1MAPT | |
| SCHEMBL31580602 | 0.79 | DPP7 (0.37) | SMYD3 | |
| SCHEMBL18382220 | 0.77 | NCF1 (0.43) | OPRL1SMYD3SQLE | |
| SCHEMBL10938895 | 0.77 | EPHX2 (0.53) | EPHX2EPHX1MAPT | |
| SCHEMBL23640028 | 0.77 | EPHX2 (0.46) | EPHX2EPHX1OPRL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| EP-2340021-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | claimed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | claimed |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | DING QINGJIE | 2010-03-25 | — | — | US | claimed |
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2340021-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011098398-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-18 | — | — | WO | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
| WO-2010031713-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | DING QINGJIE | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | EPHX2 2619/4885EPHX1 3073/4885OPRL1 2336/4885 |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | EPHX2 2619/4885EPHX1 3073/4885OPRL1 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.